Alnylam awaits FDA decisions on Amvuttra & Fitusiran next month, poised to boost revenue, profitability, and share growth.

As Alnylam Pharmaceuticals approaches its highly anticipated March 23 FDA decision date for a potential expansion of Amvuttra to treat patients in an increasingly competitive indication—transthyret | ...

Canaccord analyst Whitney Ijem raised the firm’s price target on Alnylam (ALNY) to $385 from $384 and keeps a Buy rating on the shares. The ...

Q4 2024 Management View CEO Yvonne Greenstreet highlighted 2024 as a strong year with $1.6 billion in net product revenues, achieving the upper end of the revised guidance. She emphasized the positive ...

Q4 2024 Earnings Call Transcript February 13, 2025 Alnylam Pharmaceuticals, Inc. misses on earnings expectations. Reported ...

Alnylam Pharmaceuticals exceeded Wall Street's expectations with strong revenue growth and significant commercial progress.

Amvuttra is the medicine that can reduce the amount of abnormal proteins in your body to help decrease symptoms and possibly prevent further nerve damage. Hereditary transthyretin-mediated ...

Like other drugs, Amvuttra (vutrisiran) can cause side effects, such as difficulty breathing and low vitamin A levels. If you can’t tolerate side effects of Amvuttra, talk with your doctor.

BridgeBio could be an acquisition target, but current financial challenges and competition suggest a "Hold" rating until ...

Amvuttra (vutrisiran) is a prescription drug that’s used to treat nerve damage related to a rare genetic condition. Amvuttra is given as an injection under your skin by a healthcare professional.

Alnylam Pharmaceuticals Inc (ALNY) reports robust financial performance with a 33% revenue growth and outlines strategic ...

Alnylam Pharmaceuticals ALNY reported fourth-quarter 2024 adjusted earnings of 6 cents per share, in contrast with the Zacks Consensus Estimate of a loss of 21 cents. The company had incurred a ...